NKTR News and Press, Nektar Therapeutics From 04/14/22

Nektar and Bristol Myers Squibb Announce Update on Clinical Development Program for Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab) PR Newswire PRINCETON, N.J. and SAN FRANCISCO , April 14, 2022 /PRNewswire/ -- Nektar Therapeutics ...

Goldman Sachs equity strategists stressed the importance of pricing power for companies given a four-decade high in inflation and rising commodities prices. "Pricing power will become increasingly important in the face of continued inflation and cost pressures," David Kostin, chief U.S. equit...

After the failure of PIVOT IO, what I considered Nektar's best chance with the bempeg program, the outlook for other studies in kidney, bladder, and lung cancer is not positive. NKTR-358 (lupus, atopic dermatitis, et al) and NKTR-255 (oncology) could prove to be valuable drugs, but th...

Gainers: Randolph Bancorp (RNDB) +24%. NexImmune (NEXI) +8%. Molecular Templates (MTEM) +7%. Hyzon Motors  (HYZN) +4%. Compugen  (CGEN) +3%. Losers: Aveanna Healthcare Holdings  (AVAH) -18%. Marin Software Incorporated (MRIN) -11%. Dave & Buste...

Stanley Druckenmiller’s 13F portfolio value decreased from $3.08B to $2.76B this quarter. Duquesne increased Coupang, Carvana, Kbr, Flex, Procept Bio, and Smartsheet while decreasing Alphabet, Amazon.com, Palo Alto Networks, Starbucks, and Expedia Group. They also dropped Meta ...

Clinical-stage biotech Nektar Therapeutics (NASDAQ:NKTR) is trading higher on Tuesday after losing over half of its market cap yesterday in reaction to its failure to reach the main goals in a late-stage study for a combination therapy involving its lead asset bempegaldesleukin in melano...

NKT-214 is a modified form of human interleukin-2 (IL-2). Trials have been underway in melanoma patients with inoperable and/or metastatic disease. As we've seen through the pandemic, all attempts to modulate the immune system have to be proven eventually in human clinical trials....

The S&P 500 and Nasdaq posted losses again Monday, as stocks failed to sustain an early attempt at a rebound. Worries about the Russia-Ukraine conflict and the looming prospect of rising interest rates continued to fuel caution on Wall Street. Amid this environment, fintechs took another ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Knightscope (NASDAQ: KSCP ) stock is on the move Monday following news that the company signed onto a new development project. Source: Sundry Photography / Shutterstock.com According to a press release , Knig...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biopharmaceutical company Nektar Therapeutics (NASDAQ: NKTR ) is down big today after announcing disappointing results regarding its melanoma therapy. The news clearly displeased Nektar investors. NKTR stock has shed ...